- Reaction score
- 21
It means that the efficacy of the medicine begins to wane from the sixth month of use.
Pyrilutamide (KX-826) 1.0% and 0.5%
- Thread starter jondoeuk
- Start date
Yes.
(2026-03-18) ''In terms of efficacy: compared to the placebo group, both 1.0% BID (i.e. twice a day) group and 0.5% BID group demonstrated statistically significant therapeutic efficacy and clinical significance. The target area non-vellus hair counts (“TAHC”) of the 1.0% BID group showed an increase of 15.33 hairs/cm 2 from baseline, the TAHC of the 0.5% BID group showed an increase of 14.46 hairs/cm2 from baseline, and the TAHC of the placebo group showed an increase of 4.68 hairs/cm2 from baseline. The TAHC of the 1.0% BID group showed an increase of 10.65 hairs/cm2 from the placebo group, with statistically significant results (P<0.0001). The TAHC of the 0.5% BID group showed an increase of 9.78 hairs/cm2 from the placebo group, with statistically significant results (P<0.0001).''
''Based on results of previous clinical trials, the Company plans to communicate and initiate the NDA submission for KX-826 1.0% to the drug regulatory authorities in the PRC in the near term.''
''The Company will strive to position KX-826 as the first-in-class drug approved by regulatory authorities for the treatment of Androgenetic Alopecia in China and globally. Upon approval, KX-826 is expected to fill the current clinical gap for new drugs in Androgenetic Alopecia treatment and break the nearly 40-year treatment paradigm that has relied solely on minoxidil and finasteride.'' https://en.kintor.com.cn/news_details/22.html
Last edited:
It is critical to distinguish between a drug losing all efficacy and a drug peaking and stabilising.
According to top-line data from Kintor's year-long study, patients using 0.5% pyrilutamide twice daily still experienced significant increases in target area hair count (TAHC) and hair width (TAHW) at 52 weeks compared to where they started (baseline). https://en.kintor.com.cn/news_details/9.html
Last edited: